InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.260 0.06 (2.59%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,941 Becoming a substantial holder 8 May 2025 8:20AM $1.720 $2.260 risen by 31.40%
$2,941 Ceasing to be a substantial holder 7 May 2025 3:26PM $1.718 $2.260 risen by 31.59%
$2,941 Becoming a substantial holder 2 May 2025 2:07PM $1.855 $2.260 risen by 21.83%
$2,941 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 10:13AM $1.845 $2.260 risen by 22.49%
$2,941 Initial Director's Interest Notice 29 Apr 2025 9:37AM $1.790 $2.260 risen by 26.26%
$2,941 Director Appointment 29 Apr 2025 9:19AM $1.790 $2.260 risen by 26.26%
$2,941 Appendix 3Y for Gregory George 24 Apr 2025 9:26AM $1.700 $2.260 risen by 32.94%
$2,941 Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives 17 Apr 2025 10:07AM $1.600 $2.260 risen by 41.25%
$2,941 Notification of cessation of securities - MSB 14 Apr 2025 6:42PM $1.660 $2.260 risen by 36.14%
$2,941 Notification regarding unquoted securities - MSB 14 Apr 2025 6:38PM $1.660 $2.260 risen by 36.14%
$2,941 Application for quotation of securities - MSB 14 Apr 2025 6:31PM $1.660 $2.260 risen by 36.14%
$2,941 Notification regarding unquoted securities - MSB 14 Apr 2025 6:30PM $1.660 $2.260 risen by 36.14%
$2,941 Appendix 3Y - Silviu Itescu, Eric Rose and Philip Krause 8 Apr 2025 7:09PM $1.750 $2.260 risen by 29.14%
$2,941 Notification regarding unquoted securities - MSB 8 Apr 2025 6:56PM $1.750 $2.260 risen by 29.14%
$2,941 Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs 4 Apr 2025 9:33AM $1.875 $2.260 risen by 20.53%
$2,941 Meeting Requested with FDA on Revascor Accelerated Approval 3 Apr 2025 9:51AM $1.875 $2.260 risen by 20.53%
$2,941 First Children To Begin Treatment, Medicaid Covers Ryoncil 31 Mar 2025 9:59AM $2.020 $2.260 risen by 11.88%
$2,941 Ryoncil Is Now Available For Purchase In The United States 27 Mar 2025 10:12AM $2.150 $2.260 risen by 5.12%
$2,941 Ryoncil Published in All Four Major Drug Pricing Compendia 14 Mar 2025 9:57AM $2.080 $2.260 risen by 8.65%
$2,941 CEO Presentation at ISCT North America 13 Mar 2025 9:54AM $2.040 $2.260 risen by 10.78%
$2,941 Appendix 3Y for Gregory George 13 Mar 2025 9:50AM $2.040 $2.260 risen by 10.78%
$2,941 CEO to Deliver Featured Presentation at ISCT North America 12 Mar 2025 6:24PM $2.040 $2.260 risen by 10.78%
$2,941 Appendix 3Y and replacement Appendix 3X for Gregory George 7 Mar 2025 10:14AM $2.170 $2.260 risen by 4.15%
$2,941 Appendix 3Y for Jane Bell 7 Mar 2025 10:11AM $2.170 $2.260 risen by 4.15%
$2,941 Notification regarding unquoted securities - MSB 7 Mar 2025 10:07AM $2.190 $2.260 risen by 3.20%

176 - 200 of 1201 results

Page 8 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.